行情

SEEL

SEEL

Seelos Therapeutics Inc
NASDAQ

实时行情|Nasdaq Last Sale

1.220
-0.060
-4.69%
已收盘, 16:30 09/18 EDT
开盘
1.270
昨收
1.280
最高
1.310
最低
1.220
成交量
24.26万
成交额
--
52周最高
12.82
52周最低
1.160
市值
3,141.77万
市盈率(TTM)
-0.1268
分时
5日
1月
3月
1年
5年

分析师评级

2位分析师的综合评级

买入

免责声明:分析师观点仅供投资者决策参考,不构成任何买卖投资建议。

EPS

SEEL 新闻

  • 全球16万亿美元的负收益债券已成新的“有毒资产”?
  • 澎湃新闻.55分钟前
  • 随着刺激加码 欧洲央行向银行提供34亿欧元免费贷款
  • 新浪财经.59分钟前
  • 日本据悉在推迟向韩国出口芯片生产的关键材料
  • 新浪财经综合.1小时前
  • 沪指尾盘拉升 美联储宣布降息、美股先抑后扬
  • 新浪财经.1小时前

更多

所属板块

制药
+0.10%
制药与医学研究
-0.05%

热门股票

名称
价格
涨跌幅

SEEL 简况

Seelos Therapeutics, Inc., formerly Apricus Biosciences, Inc., is a clinical-stage biopharmaceutical company. The Company is focused on developing technologies and therapeutics for the treatment of central nervous system, respiratory disorders. The Company is engaged in developing its lead programs SLS-002 and SLS-006. The Company is also engaged in developing several preclinical programs, which include SLS-008, SLS-007 SLS-010 and SLS-012. SLS-002 is intranasal racemic ketamine with two investigational new drug applications (INDs), for the treatment of suicidality in post-traumatic stress disorder (PTSD), and in depressive disorder. SLS-006 is engaged in advancing their product candidate into late stage trials as a monotherapy in early stage Parkinson's disease patients, and as an adjunctive therapy with reduced doses of Levodapa (L-DOPA). SLS-007 is a peptide-based approach, targeting the nonamyloid component core (NACore).
展开

Webull提供Seelos Therapeutics Inc的股票价格,实时市场报价,专业分析师评级,深度图表和免费的股票新闻,以帮助您做出投资决策。